HBM Holdings (HKSE:02142) Other Financing : HK$-32.5 Mil (TTM As of Dec. 2024)

View and export this data going back to 2020. Start your Free Trial

What is HBM Holdings Other Financing?

HBM Holdings's Other Financing for the six months ended in Dec. 2024 was HK$-20.2 Mil.

HBM Holdings's Other Financing for the trailing twelve months (TTM) ended in Dec. 2024 was HK$-32.5 Mil.

HBM Holdings Other Financing Historical Data

The historical data trend for HBM Holdings's Other Financing can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

HBM Holdings Other Financing Chart

HBM Holdings Annual Data

Trend

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

Other Financing

Get a 7-Day Free Trial

-68.68

-1.27

-18.23

-26.33

-27.39

HBM Holdings Semi-Annual Data
	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23	Jun24	Dec24
Other Financing	Get a 7-Day Free Trial								-12.14	-17.23	-14.68	-12.25	-20.20

HBM Holdings Other Financing Calculation

Other Financing represents other cash flow from financing activity that not otherwise classified, which includes:
Proceeds From Stock Option Exercised
Other Financing Charges

Other Financing for the trailing twelve months (TTM) ended in Dec. 2024 adds up the semi-annually data reported by the company within the most recent 12 months, which was HK$-32.5 Mil.

HBM Holdings Other Financing Related Terms

Thank you for viewing the detailed overview of HBM Holdings's Other Financing provided by GuruFocus.com. Please click on the following links to see related term pages.

HBM Holdings Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » HBM Holdings Ltd (HKSE:02142) » Definitions » Other Financing

Comparable Companies

Traded in Other Exchanges

HBMHF:USA 6XY:Germany

Address

218 Xinghu Street, Suite 202, Building A3, Suzhou Industrial Park, Suzhou, CHN, 215123

Website

https://www.harbourbiomed.com

HBM Holdings Ltd is a clinical-stage biopharmaceutical company engaged in the discovery and development of differentiated antibody therapeutics in immunology and oncology disease areas. Its products under development are Batoclimab, for the treatment of a wide spectrum of autoimmune diseases; Tanfanercept, for the treatment of moderate-to-severe dry eye disease (DED); HBM4003; HBM9378, to prevent and treat COVID-19, the pandemic respiratory disease caused by the SARS-CoV-2 virus; HBM7008; and others. Its geographical segments are Mainland China, United States, Europe, and others. The majority of the revenue for the firm is generated from the United States.

Executives

Jpmorgan Chase & Co.	2201 Interest of corporation controlled by you
Wang Jingsong	2101 Beneficial owner
Advantech Capital L.p.
Pang Kee Chan Hebert
Golden Link Investment Limited
Advantech Capital Partners Ltd.
Advantech Master Investment Limited
Astrazeneca Plc	2201 Interest of corporation controlled by you
Gic Private Limited	2102 Investment manager
The Capital Group Companies, Inc.	2201 Interest of corporation controlled by you
Gic (ventures) Pte. Ltd.	2201 Interest of corporation controlled by you
Gic Special Investments Private Limited	2102 Investment manager
Owap Investment Pte Ltd	2101 Beneficial owner
Advantech Capital Holdings Ltd.
Jun Lian Zi Ben Guan Li Gu Fen You Xian Gong Si	2201 Interest of corporation controlled by you

HBM Holdings Headlines

No Headlines